SCHEMBL5555862

SCHEMBL5555862

CCCCNC(=O)C1c2cc(Br)ccc2OC(C(C)C)C(=O)N1C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
NPC1 O15118 2/20 0.43
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SLC2A1 P11166 1/20 0.41
MCHR1 Q99705 1/20 0.41
MAOB P27338 4/20 0.40
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
SLC6A12 P48065 1/20 0.39
SLC6A13 Q9NSD5 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
ACKR3 P25106 1/20 0.39
FPR2 P25090 1/20 0.38
BCHE P06276 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5555788 0.88 KMT2A (0.43) KMT2ASMN1; SMN2MCHR1MAOBSLC6A12
SCHEMBL5562138 0.86 NPC1 (0.47) KMT2ANPC1LMNARAB9ASMN1; SMN2
SCHEMBL5561854 0.85 ACHE (0.47) NPC1LMNARAB9ASMN1; SMN2L3MBTL1
SCHEMBL5561225 0.83 ACKR3 (0.45) SMN1; SMN2SLC6A12ACKR3
SCHEMBL5561609 0.81 DRD4 (0.43) KMT2ALMNAALDH1A1ACKR3
SCHEMBL5562075 0.79 XIAP (0.39) KMT2ALMNAL3MBTL1POLBCYP2D6
SCHEMBL5556688 0.79 NR2F2 (0.39) KMT2AMCHR1MAOBSLC6A12SLC6A13
SCHEMBL5556352 0.78 KMT2A (0.43) KMT2AMAOBACKR3FPR2BCHE
SCHEMBL5557170 0.78 ACKR3 (0.44) KMT2ALMNAMAOBALDH1A1ACKR3
SCHEMBL5562323 0.77 KCNH2 (0.39) KMT2ALMNARAB9ASMN1; SMN2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631296-B1 2,3,4,5-TETRAHYDROBENZO¬F|¬1,4|OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE HOFFMANN LA ROCHE (CH) 2007-04-25 EP disclosed
US-7060698-B2 Benzoxazepinone derivatives HOFFMANN-LA ROCHE INC. (US) 2006-06-13 US disclosed
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. HOFFMANN-LA ROCHE INC. 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. BACE1, BACE2, PSEN1 KMT2A 1779/4885NPC1 1062/4885LMNA 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.